drugset / Trial / NCT05930028

A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia

NCT05930028

Phase 3 Completed 148 enrolled Boryung Pharmaceutical Co., Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this clinical study is to evaluate the efficacy and safety by comparing BR1017A+BR1017B treatment group to BR1017A treatment group and BR1017B treatment group respectively at Week 8 in essential hypertension patients with primary hypercholesterolemia

Timeline

Start
2023-07-13
Primary completion
2024-09-05
Completion
2024-09-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule
Subject Ezetimibe Unknown
Subject Fimasartan Small molecule